{"title":"间充质干细胞治疗急性肺损伤的最新进展","authors":"Jinfeng Liang, Weiyou Dai, Shihang Xue, Feifei Wu, Enhai Cui, Ruolang Pan","doi":"10.1007/s10561-024-10129-0","DOIUrl":null,"url":null,"abstract":"<p>Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening diseases in critically ill patients. Although pathophysiology of ALI/ARDS has been investigated in many studies, effective therapeutic strategies are still limited. Mesenchymal stem cell (MSC)-based therapy is emerging as a promising therapeutic intervention for patients with ALI. During the last two decades, researchers have focused on the efficacy and mechanism of MSC application in ALI animal models. MSC derived from variant resources exhibited therapeutic effects in preclinical studies of ALI with different mechanisms. Based on this, clinical studies on MSC treatment in ALI/ARDS has been tried recently, especially in COVID-19 caused lung injury. Emerging clinical trials of MSCs in treating COVID-19-related conditions have been registered in past two years. The advantages and potential of MSCs in the defense against COVID-19-related ALI or ARDS have been confirmed. This review provides a brief overview of recent research progress in MSC-based therapies in preclinical study and clinical trials in ALI treatment, as well as the underlying mechanisms.</p>","PeriodicalId":9723,"journal":{"name":"Cell and Tissue Banking","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recent progress in mesenchymal stem cell-based therapy for acute lung injury\",\"authors\":\"Jinfeng Liang, Weiyou Dai, Shihang Xue, Feifei Wu, Enhai Cui, Ruolang Pan\",\"doi\":\"10.1007/s10561-024-10129-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening diseases in critically ill patients. Although pathophysiology of ALI/ARDS has been investigated in many studies, effective therapeutic strategies are still limited. Mesenchymal stem cell (MSC)-based therapy is emerging as a promising therapeutic intervention for patients with ALI. During the last two decades, researchers have focused on the efficacy and mechanism of MSC application in ALI animal models. MSC derived from variant resources exhibited therapeutic effects in preclinical studies of ALI with different mechanisms. Based on this, clinical studies on MSC treatment in ALI/ARDS has been tried recently, especially in COVID-19 caused lung injury. Emerging clinical trials of MSCs in treating COVID-19-related conditions have been registered in past two years. The advantages and potential of MSCs in the defense against COVID-19-related ALI or ARDS have been confirmed. This review provides a brief overview of recent research progress in MSC-based therapies in preclinical study and clinical trials in ALI treatment, as well as the underlying mechanisms.</p>\",\"PeriodicalId\":9723,\"journal\":{\"name\":\"Cell and Tissue Banking\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-03-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell and Tissue Banking\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1007/s10561-024-10129-0\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell and Tissue Banking","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s10561-024-10129-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
急性肺损伤（ALI）和急性呼吸窘迫综合征（ARDS）是危重病人危及生命的疾病。尽管许多研究已对ALI/ARDS的病理生理学进行了调查，但有效的治疗策略仍然有限。以间充质干细胞（MSC）为基础的疗法正在成为ALI患者的一种有希望的治疗干预手段。在过去二十年中，研究人员一直在关注间充质干细胞应用于 ALI 动物模型的疗效和机制。在 ALI 的临床前研究中，来自不同资源的间充质干细胞表现出了不同机制的治疗效果。在此基础上，最近又尝试了间充质干细胞治疗 ALI/ARDS 的临床研究，尤其是在 COVID-19 引起的肺损伤中。在过去的两年中，间充质干细胞治疗 COVID-19 相关疾病的临床试验崭露头角。间充质干细胞在防御 COVID-19 相关 ALI 或 ARDS 方面的优势和潜力已得到证实。本综述简要概述了基于间充质干细胞疗法的临床前研究和临床试验在治疗ALI方面的最新研究进展及其内在机制。
Recent progress in mesenchymal stem cell-based therapy for acute lung injury
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening diseases in critically ill patients. Although pathophysiology of ALI/ARDS has been investigated in many studies, effective therapeutic strategies are still limited. Mesenchymal stem cell (MSC)-based therapy is emerging as a promising therapeutic intervention for patients with ALI. During the last two decades, researchers have focused on the efficacy and mechanism of MSC application in ALI animal models. MSC derived from variant resources exhibited therapeutic effects in preclinical studies of ALI with different mechanisms. Based on this, clinical studies on MSC treatment in ALI/ARDS has been tried recently, especially in COVID-19 caused lung injury. Emerging clinical trials of MSCs in treating COVID-19-related conditions have been registered in past two years. The advantages and potential of MSCs in the defense against COVID-19-related ALI or ARDS have been confirmed. This review provides a brief overview of recent research progress in MSC-based therapies in preclinical study and clinical trials in ALI treatment, as well as the underlying mechanisms.
期刊介绍：
Cell and Tissue Banking provides a forum for disseminating information to scientists and clinicians involved in the banking and transplantation of cells and tissues. Cell and Tissue Banking is an international, peer-reviewed journal that publishes original papers in the following areas:
basic research concerning general aspects of tissue banking such as quality assurance and control of banked cells/tissues, effects of preservation and sterilisation methods on cells/tissues, biotechnology, etc.; clinical applications of banked cells/tissues; standards of practice in procurement, processing, storage and distribution of cells/tissues; ethical issues; medico-legal issues.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
